Page 1

ZEAL & ZEALAND PHARMA Source : Zealand Pharma August 12 , 2021 09:00 ET Zealand Pharma Launches ZEGALOGUEⓇ ( dasiglucagon ) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas Company annoucement - No. 50/2021 Interim report for H1 2021 Zealand Pharma Launches ZEGALOGUE® ( dasiglucagon ) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas Copenhagen , DK and Boston , MA , U.S. August 12 , 2021 – Zealand Pharma A / S ( Nasdaq : ZEAL ) ( CVR - no . 20045078 ) a biotechnology company focused on the discovery , development and commercialization of innovative peptide - based medicines , today announced financial results for the first half of 2021 . Financial results for the first half of 2021 • Revenue : DKK 132.1 million / USD 21.1 million ( DKK 233.4 million / USD 35.1 million in the first six months of 2020 ) . • Net operating expenses : DKK -616.6 million / USD -98.5 million ( DKK -437.2 million / USD -65.7 million in the first six months of 2020 ) . • Net operating result : DKK -550.8 million / USD -88.0 million ( DKK -230.9 million / USD -34.7 million in the first six months of 2020 ) . • Cash , cash equivalents , and marketable securities : DKK 1,282.9 million / USD 205.0 million as of June 30 , 2021 ( June 30 , 2020 : DKK 1,665.0 million / USD 250.2 million ) . Business highlights for the first half of 2021 • Announced commercial availability of Zegalogue® ( dasiglucagon ) injection , for the treatment of severe hypoglycemia in people with diabetes aged 6 years and older . In June 2021 , ZEGALOGUE became commercially available in the U.S. , in both an auto - injector and prefilled syringe for the treatment of severe hypoglycemia in patients with diabetes aged 6 years and older . To support the ZEGALOGUE launch , the Zealand Pharma field sales team is fully training and actively engaging high volume prescribers of rescue therapies across the U.S. The team is optimally resourced to call on the Health Care Providers that contribute to over 80 % of the total rescue therapy prescription volume . Zealand Pharma has also introduced ConnectedCare ™ , a patient support program designed to facilitate patient access and offer educational and affordability resources for people with diabetes and their caregivers . • Announced the initiation of two Phase 2 trials for BI 456906 by partner Boehringer Ingelheim and Fast Track Designation from the U.S. FDA . In April 2021 , Zealand and Boehringer Ingelheim announced the initiation of two Phase 2 trials for the GLP - 1 / glucagon dual agonist for adults who are overweight or obese , and for adults with non alcoholic steatohepatitis ( NASH ) . These recently initiated studies are being performed to determine the appropriate dose in patients who are overweight or obese , and to determine the safety , efficacy and tolerability of this compound in patients with NASH and Fibrosis . In June , the U.S. FDA granted Fast Track Designation to the GLP - 1 / glucagon dual agonist for the investigational treatment of NASH . The designation facilitates the development , and expedites the review , of new therapies to treat serious conditions and fill an unmet medical need . In addition , the compound is currently being investigated in an ongoing Phase 2 study in people with type 2 diabetes mellitus . • Presented data on dasiglucagon at 81st Scientific Session of American Diabetes Association ( ADA ) and posters on glepaglutide at 17th Congress the Intestinal Rehabilitation and Transplantation Association ( CIRTA ) . Zealand had five posters and one oral poster presentation at the 81st Scientific Session of the ADA . At CIRTA 2021 , Zealand presented three posters , including data on glepaglutide that suggested dose adjustment may not be necessary when treating short bowel syndrome ( SBS ) patients with renal impairment . • Announced publication of Phase 3 trial results evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes . In May , Diabetes Care published results from the Phase 3 trial that